troglitazone has been researched along with Glial Cell Tumors in 6 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant entity." | 5.34 | The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. ( Blümcke, I; Buslei, R; Coras, R; Eyüpoglu, IY; Hahnen, E; Hauke, J; Hölsken, A; Reichel, M; Seufert, S; Siebzehnrübl, FA; Tränkle, C, 2007) |
| " Agonists of the peroxisome proliferator-activated receptor-gamma (PPARgamma), such as rosiglitazone, have been recently demonstrated to regulate inflammation by modulating the production of inflammatory mediators and adhesion molecules." | 3.73 | Rosiglitazone ameliorates cisplatin-induced renal injury in mice. ( Jang, KY; Jang, YB; Kang, KP; Kim, DH; Kim, W; Lee, JE; Lee, S; Moon, SO; Park, SK; Sung, MJ, 2006) |
| "Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant entity." | 1.34 | The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. ( Blümcke, I; Buslei, R; Coras, R; Eyüpoglu, IY; Hahnen, E; Hauke, J; Hölsken, A; Reichel, M; Seufert, S; Siebzehnrübl, FA; Tränkle, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grund, K | 1 |
| Ahmadi, R | 1 |
| Jung, F | 1 |
| Funke, V | 1 |
| Gdynia, G | 1 |
| Benner, A | 1 |
| Sykora, J | 1 |
| Walczak, H | 1 |
| Joos, S | 1 |
| Felsberg, J | 1 |
| Reifenberger, G | 1 |
| Wiestler, OD | 1 |
| Herold-Mende, C | 1 |
| Roth, W | 1 |
| Hollander, AB | 1 |
| Dorsey, JF | 1 |
| Akasaki, Y | 1 |
| Liu, G | 1 |
| Matundan, HH | 1 |
| Ng, H | 1 |
| Yuan, X | 1 |
| Zeng, Z | 1 |
| Black, KL | 1 |
| Yu, JS | 1 |
| Lee, S | 1 |
| Kim, W | 1 |
| Moon, SO | 1 |
| Sung, MJ | 1 |
| Kim, DH | 1 |
| Kang, KP | 1 |
| Jang, YB | 1 |
| Lee, JE | 1 |
| Jang, KY | 1 |
| Park, SK | 1 |
| Spagnolo, A | 1 |
| Grant, EN | 1 |
| Glick, R | 1 |
| Lichtor, T | 1 |
| Feinstein, DL | 1 |
| Coras, R | 1 |
| Hölsken, A | 1 |
| Seufert, S | 1 |
| Hauke, J | 1 |
| Eyüpoglu, IY | 1 |
| Reichel, M | 1 |
| Tränkle, C | 1 |
| Siebzehnrübl, FA | 1 |
| Buslei, R | 1 |
| Blümcke, I | 1 |
| Hahnen, E | 1 |
6 other studies available for troglitazone and Glial Cell Tumors
| Article | Year |
|---|---|
Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD.
Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; CASP8 and FADD-Like Apoptosis Regula | 2008 |
FLIPing the apoptosis switch on in brain tumors using Troglitazone and TRAIL.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Chromans; Glioblastoma; Glioma; Humans; | 2008 |
A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspase 8; Caspase 9; Caspases; Chr | 2006 |
Rosiglitazone ameliorates cisplatin-induced renal injury in mice.
Topics: Anilides; Animals; Apoptosis; C-Peptide; Cell Line; Chromans; Cisplatin; Drug Evaluation, Preclinica | 2006 |
Differential effects of PPARgamma agonists on the metabolic properties of gliomas and astrocytes.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Surv | 2007 |
The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Chromans; DNA Primers; Dow | 2007 |